Antihypertensive and organ-protective effects of benazepril

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 12, 2010, Pages 1653-1671

  Barrios, Vivencio ^a   Escobar, Carlos ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

ACE inhibitors; atrial fibrillation; benazepril; cardiovascular protection; combination therapy; congestive heart failure; hypertension; renal protection

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENAZEPRILAT; CAPTOPRIL; CILAZAPRIL; DIGOXIN; ENALAPRIL; FELODIPINE; PERINDOPRIL; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CONGESTIVE HEART FAILURE; COUGHING; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PROTECTION; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; NAUSEA; PAIN; RENAL PROTECTION; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BENZAZEPINES; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY; PRACTICE GUIDELINES AS TOPIC; PRODRUGS; SOCIETIES, MEDICAL;

EID: 78649649431     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.159     Document Type: Review

References (136)

1. Bicket DP. Using ACE inhibitors appropriately. Am. Fam. Physician 66, 461-468 (2002).
2. Mancia G, De Backer G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105-1187 (2007). (Pubitemid 46924065)
3. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335, 765-774 (1990).
4. Prospective Studies Collaboration. Age-specifc relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002).
5. Mancia G, Laurent S, Agabiti-Roseic E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27, 2121-2158 (2009).
6. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
7. Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, b-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens. 14, 241-247 (2001).
8. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353, 2008-2013 (1999).
9. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br. Med. J. 326, 1427 (2003).
10. Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam. Clin. Pharmacol. 24, 3-8 (2010).
11. Barrios V, Escobar C, Divisón JA, Medialdea F. Low-dose fxed combination of perindopril plus indapamide in the diabetic hypertensive population. Expert Rev. Cardiovasc. Ther. 6, 1063-1069 (2008).
12. Rosenthal T, Gavras I. Fixed-drug combinations as frst-line treatment for hypertension. Prog. Cardiovasc. Dis. 48, 416-425 (2006).
13. Barrios V, Escobar C, Echarri R. Fixed combinations in the management of hypertension: perspective on lercanidipine-enalapril. Vasc. Health Risk Manag. 4, 847-853 (2008).
14. Barrios V. Combined therapy: the future has already come. Fundam. Clin. Pharmacol. 24, 2 (2010).
15. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122, 290-300 (2009).
16. Destro M, Cagnoni F, D'Ospina A et al. Role of valsartan, amlodipine and hydrochlorothiazide fxed combination in blood pressure control: an update. Vasc. Health Risk Manag. 6, 253-260 (2010).
17. Schmeider RE. The role of fxed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm. Clin. Exp. Hypertens. 32, 35-42 (2010).
18. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br. J. Pharmacol. 160, 1273-1292 (2010).
19. Campbell NR, Khan NA, Hill MD et al. 2009 Canadian Hypertension Education Program recommendations: the scientifc summary-an annual update. Can. J. Cardiol. 25, 271-277 (2009).
20. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fxed-dose combination versus separate antihypertensive agents. Am. J. Health Syst. Pharm. 64, 1279-1283 (2007).
21. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120, 713-719 (2007).
22. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fxed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55, 399-407 (2010).
23. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, 391-479 (2009).
24. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J. Clin. Invest. 65, 1257-1264 (1980).
25. Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J. Pharmacol. Exp. Ther. 279, 703-712 (1996).
26. Gainer J V, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. 339, 1285-1292 (1998)
27. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J. Am. Coll. Cardiol. 2, 755-763 (1983).
28. Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70, 271-278 (1984).
29. Cleland JG, Dargie HJ, Hodsman GP et al. Captopril in heart failure: a double blind controlled trial. Br. Heart J. 52, 530-535 (1984).
30. Cleland JG, Dargie HJ, Ball SG et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br. Heart J. 54, 305-312 (1985)
31. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429-1435 (1987).
32. Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M, for the Fosinopril Effcacy/Safety Trial (FEST) Study Group. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur. Heart J. 16, 1892-1899 (1995).
33. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin. J. Am. Soc. Nephrol. 1, 8-18 (2006).
34. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 14, 1-113 (2007).
35. Chronic Kidney Prognosis Consortium. Association of estimated glomerular fltration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073-2081 (2010).
36. Ruggenenti P, Fassi A, Ilevia AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 351, 1941-1951 (2004).
37. Brenner B, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
38. Lewis E, Hunsicker LG, Clarke WR, Berl T et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
39. Lewis E, Hunsicker LG, Bain R P, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456-1462 (1993).
40. Fogari R, Zoppi A, Tettamanti F, Tettamanzi D, Lusardi P, Motolese M. Fixed combination of benazepril and very low dose hydrochlorothiazide in the treatment of mild to moderate essential hypertension: evaluation by 24-hour non invasive ambulatory blood pressure monitoring. Int. J. Clin. Pharmacol. Ther. 32, 606-611 (1994).
41. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 73, 1303-1309 (2008).
42. Whalen JJ. Defnition of the effective dose of the converting-enzyme inhibitor benazepril. Am. Heart J. 117, 728-734 (1989).
43. Kaiser G. Benazepril-pharmacokinetic profle in specifc subpopulations. In: Benazepril: Profle of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 29-39 (1990).
44. Chen DS, Dotson RA, Burrell RD, Watkins BE. Two potent angiotensin-converting enzyme (ACE) inhibitors: CGS 14 824 A and CGS 14 831. Pharmacologist 25, 240 (1983).
45. Balfour JA, Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic effcacy in hypertension and congestive heart failure. Drugs 42, 511-539 (1991).
46. Chen B, Perich R, Jackson B et al. Inhibition of tissue ACE by benazepril. In: Benazepril: Profle of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 17-27 (1990).
47. Johnston CI, Cubela R, Jackson B. Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat. Clin. Exp. Pharmacol. Physiol. 15, 123-129 (1988).
48. Johnston CI, Fabris B, Yamada H et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J. Hypertens. 7, 11-16 (1989).
49. Norman JA, Lehmann M, Goodman FR, Barclay BW, Zimmerman MB. Central and peripheral inhibition of angiotensin converting enzyme (ACE) in the SHR: correlation with the antihypertensive activity of ACE inhibitors. Clin. Exp. Hypertens. A 9, 461-468 (1987). (Pubitemid 17096578)
50. Zimmerman MB, Barclay BW, Lehmann M, Norman JA. Effects of chronic administration of angiotensin converting enzyme (ACE) inhibitors on blood pressure and tissue ACE activity in the SHR. Clin. Exp. Hypertens. A 9, 473-476 (1987). (Pubitemid 17096580)
51. Bidiville J, Porchet M, Bussien JP, Nussberger J, Waeber B, Brunner HR. Effect of eight-day converting enzyme inhibition on ambulatory blood pressure recordings in normotensive volunteers. Arch. Int. Pharmacodyn. Ther. 288, 109-119 (1987). (Pubitemid 17122690)
52. Juillerat L, Nussberger J, Ménard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16, 564-572 (1990).
53. Schaller MD, Nussberger J, Waeber B et al. Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers. Eur. J. Clin. Pharmacol. 28, 267-272 (1985).
54. Waeber G, Fasanella d'Amore T, Nussberger J, Waeber B, Brunner HR. Effect on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A. Eur. J. Clin. Pharmacol. 31, 643-646 (1987).
55. Insel J, Mirvis DM, Boland MJ et al. A multicenter study of the safety and effcacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. Clin. Pharmacol. Ther. 45, 312-320 (1989).
56. Bedogna V, Valvo E, Casagrande P et al. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int. 38, 101-107 (1990).
57. Ribner HS, Sagar KB, Glasser SP et al. Long-term therapy with benazepril in patients with congestive heart failure: effects on clinical status and exercise tolerance. J. Clin. Pharmacol. 30, 1106-1111 (1990).
58. Nussberger J, de Gasparo M, Juillerat L et al. Rapid measurement of total and active renin: plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A. Clin. Exp. Hypertens. A 9, 1353-1366 (1987).
59. Nussberger J, Juillerat L, Perret F et al. Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. Am. Heart J. 117, 717-722 (1989).
60. Agabiti-Rosei E, Rizzoni D, Zulli R et al. Sustained antihypertensive effects of benazepril demonstrated by ambulatory monitoring: placebo-controlled trial at two dosage levels. In: Benazepril: Profle of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 59-66 (1990).
61. Oldenbroek C. Invasive 24-hour blood pressure monitoring in controlled trial of benazepril. In: Benazepril: Profle of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 67-75 (1990).
62. Pessina AC, Mormino P, Palatnini P et al. Morning or evening benazepril administration in hypertension? A randomized study using intra-arterial blood pressure monitoring. In: Benazepril: Profle of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 59-65 (1990).
63. Weinberger MH, Black HR, Lasseter KC et al. Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril hydrochloride. Clin. Pharmacol. Ther. 47, 608-617 (1990).
64. Rousseau MF, Gurné O, van Eyll C, Benedict CR, Pouleur H. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohumoral status in patients with ischemic heart disease. Circulation 81, 123-129 (1990).
65. Noormohamed FH, Fuller GN, Lant AF. Effect of salt balance on the renal and hemodynamic actions of benazepril in normal men. J. Clin. Pharmacol. 29, 928-937 (1989).
66. Valvo E, Casagrande P, Bedogna V et al. Systemic and renal effects of a new angiotensin converting enzyme inhibitor, benazepril, in essential hypertension. J. Hypertens. 8, 991-995 (1990).
67. Reams GP, Lau A, Bauer JH. Effect of benazepril monotherapy in subjects with hypertension associated with renal dysfunction. J. Clin. Pharmacol. 29, 609-614 (1989).
68. Kaiser G, Ackermann R, Brechbühler S, Dieterle W. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. Biopharm. Drug Dispos. 10, 365-376 (1989).
69. 14C]-benazepril hydrochloride in rat, dog and baboon. Absorption, distribution, kinetics, biotransformation and excretion. Arzneimittelforschung 39, 62-67 (1989).
70. Kaiser G, Ackermann R, Gschwind HP et al. The infuence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride. Biopharm. Drug Dispos. 11, 753-764 (1990).
71. 14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. Xenobiotica 21, 251-261 (1991).
72. Kaiser G, Ackermann R, Dieterle W et al. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. Eur. J. Clin. Pharmacol. 38, 379-385 (1990).
73. Gengo FM, Brady E. The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin. Cardiol. 14, 44-55 (1991).
74. MacDonald NJ, Elliott HL, Howie CA, Reid JL. Age and the pharmacodynamics and pharmacokinetics of benazepril. Br. J. Clin. Pharmacol. 27, 707-708 (1989).
75. MacNab M, Mallows S. Safety profle of benazepril in essential hypertension. Clin. Cardiol. 14, 33-37 (1991).
76. Ohnishi A, Tsuboi Y, Ishizaki T et al. Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin. Pharmacol. Ther. 45, 657-665 (1989).
77. Kaiser G, Ackermann R, Siouf A. Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am. Heart J. 117, 746-751 (1989).
78. Guyene TT, Bellet M, Sassano P, Serrurier D, Corvol P, Ménard J. Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension. J. Hypertens. 7, 1005-1012 (1989).
79. Hayes PC, Plevris JN, Bouchier IA. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. J. Hum. Hypertens. 3, 153-158 (1989).
80. DeQuattro V. Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide. Clin. Cardiol. 14, 28-55 (1991).
81. Smith WM, Gomez HJ. The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol.14, 79-90 (1991).
82. Bellet M, Whalen JJ, Bodin F, Serrurier D, Tanner K, Ménard J. Use of crossover trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril. J. Hypertens. 8, 43-48 (1990).
83. Francillon A, Heintzmann F, Serrurier D. Effcacy of benazepril as replacement therapy after failure of a frst antihypertensive treatment. Therapie 49, 95-99 (1994).
84. Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low-and high-dose combinations, on blood pressure in patients with hypertension. Arch. Fam. Med. 5, 17-25 (1996).
85. Holwerda K, Hoogma RP, Oldenbroek C, Huige RC, Wester A, Rijnierse JM. Effcacy and safety of benazepril plus hydrochlorothiazide versus benazepril alone in hypertensive patients unresponsive to benazepril monotherapy. Clin. Ther. 16, 942-951 (1994).
86. Haziza HM, Francillon A, Mottier D, Heintzmann F, Serrurier D. [Antihypertensive action and predictive factors of effcacy of benazepril in mild-to-moderate hypertension: clinical trial in general medical practice on 16,987 patients.] Ann. Cardiol. Angélol. 47, 33-41 (1998).
87. Adalet K, Nalbantgil I, Kiliççioglu B et al. Multicenter double blind comparative trial with benazepril versus captopril in the treatment of mild to moderate hypertension. Med. Bull. Istanbul 28, 2 (1995).
88. Fogari R, Zoppi A, Lusardi P, Mugellini A, Bertocchi F. Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodipine extended release in elderly patients with mild-to-moderate essential hypertension. Curr. Therap. Res. 59, 246-256 (1998).
89. Izzo JL Jr, Purkayastha D, Hall D, Hilkert RJ. Comparative effcacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. J. Hum. Hypertens. 24, 403-409 (2010).
90. Ueng KC, Lin LC, Voon WC et al. An eight-week, multicenter, randomized, double-blind study to evaluate the effcacy and tolerability of fxed-dose amlodipine/benazepril combination in comparison with amlodipine as frst-line therapy in Chinese patients with mild to moderate hypertension. Blood Press. Suppl. 1, 24-31 (2008).
91. Jamerson K, Bakris GL, Dahlöf B et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 16, 80-86 (2007).
92. Jamerson KA. The frst hypertension trial comparing the effects of two fxed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH). J. Clin. Hypertens. 5, 29-35 (2003).
93. Bramlage P. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin. Pharmacother. 10, 1755-1767 (2009).
94. Bakris GL, Sarafdis PA, Weir MR et al. Renal outcomes with different fxed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecifed secondary analysis of a randomised controlled trial. Lancet 375, 1173-1181 (2010).
95. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417-2428 (2008).
96. Weber MA, Bakris GL, Jamerson K et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J. Am. Coll. Cardiol. 56, 77-85 (2010).
97. Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet 336, 370-371 (1990).
98. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 362, 1527-1535 (2003).
99. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358, 1887-1898 (2008).
100. ALLHAT Offcers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).
101. Escobar C, Echarri R, Barrios V. Combined therapy in the treatment of hypertension: but which? J. Hypertens. 27, 1331 (2009).
102. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specifc relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002).
103. Colfer HT, Ribner HS, Gradman A, Hughes V, Kapoor A, Laidlaw JC. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am. J. Cardiol. 70, 354-358 (1992).
104. Nordrehaug JE, Omsjø IH, Vollset SE. A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure. J. Intern. Med. 231, 589-594 (1992).
105. Ye JF, Liu DS. Effects of benazepril combined with valsartan on congestive heart failure. Di Yi Jun Yi Da Xue Xue Bao 25, 1441-1447 (2005).
106. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classifcation, and stratifcation. Am. J. Kidney Dis. 39, 1-266 (2002).
107. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insuffciency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insuffciency Study Group. N. Engl. J. Med. 334, 939-945 (1996).
108. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular fltration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857-1863 (1997).
109. Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol. 9, 2096-2101 (1998).
110. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med. 160, 685-693 (2000).
111. Hou FF, Zhang X, Zhang GH et al. Effcacy and safety of benazepril for advanced chronic renal insuffciency. N. Engl. J. Med. 354, 131-140 (2006).
112. Zhang GH, Hou FF, Zhang X, Liu QF. Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/l? Zhonghua Nei Ke Za Zhi 44, 592-596 (2005).
113. Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Effcacy in Nephropathy. J. Am. Soc. Nephrol. 12, 2832-2837 (2001).
114. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int. 53, 1209-1216 (1998).
115. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insuffciency: a controlled double-blind trial. Am. J. Kidney. Dis. 27, 489-495 (1996).
116. Ishimitsu T, Akashiba A, Kameda T et al. Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology 12, 294-298 (2007).
117. Shoda J, Kanno Y, Suzuki H. A fve-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern. Med. 45, 193-198 (2006).
118. De Cesaris R, Ranieri G, Andriani A et al. Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. Clin. Pharmacol. Ther. 60, 472-478 (1996).
119. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285, 2719-2728 (2001).
120. Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern. Med. 163, 1555-1565 (2003).
121. Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 43, 260-268 (2004).
122. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type I diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol. 14, 992-999 (2003).
123. Barrios V, Escobar C. Antihypertensive agents: are all of them equal? South. Med. J. 101, 779-780 (2008).
124. Wyndham CRC, Atrial fbrillation: the most common arrhythmia. Tex. Heart Inst. J. 27, 257-267 (2000).
125. Zaman Ag, Kearney MT, Schecter C, Worthley SG, Nolan J. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fbrillation. Am. Heart J. 147, 823-827 (2004).
126. Liu L, Qu XF, Yu Y, Bai B, Huang YL. Effect of benazepril on atrial cytoskeleton remodeling in the canine atrial fbrillation models. Zhonghua Yi Xue Za Zhi 89, 2718-2721 (2009).
127. Pethica BD. Safety and tolerability of benazepril in the treatment of hypertension-an overview. In: Benazepril: Profle of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 161-167 (1990).
128. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. 117, 234-242 (1992).
129. Amir M, Khan B, Tahir M. Incidence of angiotensin converting enzyme inhibitor induced cough. Prof. Med. J. 12, 435-439 (2005).
130. Lu J, Li LM, Cao WH, Zhan SY, Hu YH. Postmarketing surveillance on Benazepril. Zhonghua Liu Xing Bing Xue Za Zhi 25, 412-416 (2004).
131. Tomlinson B, Woo J, Thomas GN, Chau YM, Critchley JA. Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult chinese patients with hypertension. Clin. Ther. 26, 1292-1304 (2004).
132. Slater EE, Merrill DD, Guess HA et al. Clinical profle of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260, 967-970 (1988).
133. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
134. Barrios V, Banegas JR, Ruilope LM, Rodicio JL. Evolution of blood pressure control in Spain. J. Hypertens. 25, 1975-1977 (2007).
135. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensifcation, and control in Western Europe and the United States. Arch. Intern. Med. 167, 141-147 (2007).
136. Ninomiya T, Perkovic V, de Galan et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 27, 172-181 (2007).